{'fraction_non_alphanumeric': 0.029439696106362774, 'fraction_numerical': 0.010446343779677113, 'mean_word_length': 5.426829268292683, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 1, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The course forward: next generation sequencing as part of the next generation management of patients with locally advanced cervical cancer.

https://ejgo.org In the era of increasingly personalized oncology and molecularly-driven treatment approaches, Kim et al. [1] address the relative lack of predictive biomarkers for response to definitive radiation therapy (RT) in patients with locally advanced cervical cancer (LACC). Of 528 such patients with available formalin-fixed paraffin-embedded tumor specimens, the authors identified 26 patients who experienced recurrence within 36 months of completing therapy—the so-called no durable benefit (NDB) group, and propensity matched those for tumor features to patients who remained alive and disease free for at least 5 years—termed the durable clinical benefit (DCB) group – before processing the tumor specimens for transcriptomics analysis. After RNA extraction and quality control, they were unfortunately left with only a small cohort of 4 NDB and 5 DCB patients on which to perform their analysis.